BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,316.80
- Market cap
- ₹65,386 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.4×Sector 46.1×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Other board meeting date announcements
All →Narmadesh Brass Industries Board Meeting Date
Narmadesh Brass Industries will hold a board meeting on 3 November 2026 to consider unaudited standalone results for the half year ended 30 September 2026. The filing is an advance board meeting intimation.
Panabyte Technologies Board Meeting Date
Panabyte Technologies scheduled a board meeting for November 5, 2026 to consider unaudited standalone quarterly results. Agenda items are proposed only, with no decision yet taken.
Texmaco Rail & Engineering Board Meeting Date
Texmaco Rail & Engineering will hold a board meeting on November 5, 2026 to consider unaudited standalone and consolidated results for Q2 and H1 FY27. No financial figures are disclosed in this intimation.
Sundaram-Clayton Board Meeting Date
Sundaram-Clayton convenes a board meeting on 4 November 2026 to consider quarterly results. Trading window stays closed until 6 November 2026.
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Faze Three Board Meeting Date
Faze Three Ltd intimated a board meeting on November 3, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closure is also noted.